Ignite Creation Date:
2024-05-06 @ 8:21 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06352593
Status:
RECRUITING
Last Update Posted:
2024-04-09
First Post:
2024-04-02
Brief Title:
Intraoperative Dexmedetomidine Infusion in Endovascular Intervention for Aneurysmal Subarachnoid Hemorrhage
Sponsor:
Tanta University
Organization:
Tanta University
Study Overview
Official Title:
Role of Intraoperative Dexmedetomidine Infusion in Endovascular Intervention for Aneurysmal Subarachnoid Hemorrhage A Randomized Controlled Trial
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to evaluate the role of intraoperative dexmedetomidine infusion in endovascular intervention for aneurysmal subarachnoid hemorrhage
Detailed Description:
Aneurysmal subarachnoid hemorrhage is a sudden life-threatening emergency caused by bleeding in the subarachnoid space between the brain and skull Cerebral vasospasm VSP is the leading risk factor of neurological deterioration ie delayed cerebral ischemia DCI and cerebral infarction after aneurysmal subarachnoid hemorrhage SAH and a cause of morbidity and mortality
Dexmedetomidine DEX is a highly selective α-2 adrenergic receptor agonist The α -2 receptor agonists have a long track record of use for sedation and analgesia It has been shown that α -2 agonists are neuroprotective in craniocerebral and subarachnoid injuries Dexmedetomidine has a significant effect on the central nervous system and decreases the blood flow in the brain and the requirement or needs for cerebral oxygen It also modifies memory and enhances cognitive ability effects like sedation analgesic and anxiolytics Dexmedetomidine is shown to decrease catecholamine in the brain and improves the perfusion ability in the penumbra The glutamate level is significantly reduced by Dexmedetomidine DEX and so injuries at the cellular level is reduced
Dexmedetomidine DEX is a highly selective α-2 adrenergic receptor agonist The α -2 receptor agonists have a long track record of use for sedation and analgesia It has been shown that α -2 agonists are neuroprotective in craniocerebral and subarachnoid injuries Dexmedetomidine has a significant effect on the central nervous system and decreases the blood flow in the brain and the requirement or needs for cerebral oxygen It also modifies memory and enhances cognitive ability effects like sedation analgesic and anxiolytics Dexmedetomidine is shown to decrease catecholamine in the brain and improves the perfusion ability in the penumbra The glutamate level is significantly reduced by Dexmedetomidine DEX and so injuries at the cellular level is reduced
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None